AI-Driven Supercomputing Yields Non-Toxic Cancer Drug Candidate
A new cancer drug candidate, BBO-10203, developed through supercomputing and AI, effectively blocks tumor growth by targeting the RAS-PI3Kα interaction without causing toxic side effects like hyperglycemia, showing promise in early clinical trials and representing a significant advancement in targeted cancer therapy.